Immunocore Spon Ads Each Rep One Ord Shs (IMCR) Stock
UK biotech firm developing cancer immune treatments. Here's the price, business snapshot, and what's worth knowing about Immunocore Spon Ads Each Rep One Ord Shs in July 2026.
Immunocore Holdings plc (IMCR) is a UK‑based biotechnology company focused on T‑cell receptor (TCR)‑based immunotherapies for cancer and other serious diseases. The firm is best known for developing bispecific TCR therapies that redirect a patient’s T cells to recognise and attack tumour cells. Its market capitalisation sits around $1.72 billion, reflecting a mix of commercial progress and ongoing clinical development. For investors, key things to watch are regulatory milestones, clinical trial readouts, commercial uptake of approved therapies and partnership or licensing deals that can influence revenue and R&D funding. As a clinical-stage biopharmaceutical company, Immunocore can offer upside linked to successful trials but also carries higher volatility and binary risks — trials may fail, timelines can slip and drug adoption can vary. This summary is for general, educational purposes only and not personal financial advice; suitability depends on individual circumstances and risk tolerance.
Stock Performance Snapshot
Financial Health
Immunocore is performing well with strong revenue and impressive profit margins from its operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IMCR
Pharma Stocks: Could Pipeline Power Drive Growth?
Pharmaceutical giant Roche boosted its earnings outlook, fueled by strong sales of its innovative cancer, immunology, and diagnostic products. This success highlights a broader investment opportunity in leading drugmakers with powerful research and development engines poised for growth.
Published: 23 October 2025
Explore BasketOncology Stocks: Partnership Boom or Bubble Risk?
China's Innovent Biologics and Japan's Takeda Pharmaceutical have signed a multi-billion dollar deal to co-develop advanced cancer therapies. This landmark partnership signals a growing trend of international collaborations, creating potential investment opportunities among other biotech firms specializing in immuno-oncology and antibody-drug conjugates.
Published: 22 October 2025
Explore BasketPharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: 29 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
TCR Immunotherapy Focus
Immunocore’s unique T‑cell receptor approach aims to broaden immune targeting of tumours, though clinical results and uptake can vary.
Clinical Milestones Matter
Trial readouts and regulatory decisions tend to move the share price significantly, offering potential upside alongside binary risk.
Commercial & Partnership Drivers
Revenue and scale depend on market adoption and collaborations; partnerships can de‑risk development but outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
